Want to see GB:NFX full AI Analyst Report?
NFX Stock Chart & Stats
0.23 p
<0.01 p(2.11%)
At close: 4:00 PM EST
0.23 p
<0.01 p(2.11%)
Day’s Range― - ―
52-Week Range0.07 p - 0.56 p
Previous CloseN/A
Volume1.00M
Average Volume (3M)97.88M
Market Cap
£4.44M
Enterprise Value2.97M
Total Cash (Recent Filing)£930.28K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)5.3
Beta0.02
Next Earnings
Feb 03, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,609,750,000
10 Day Avg. Volume69,476,590
30 Day Avg. Volume97,880,797
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.17
Price to Sales (P/S)0.00
P/FCF Ratio-6.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Cocrystal PlatformNuformix's proprietary cocrystal platform is a durable technical capability that can create differentiated solid-state drug forms. This provides an IP-led avenue for partnerships or licensing, reduces formulation risk for candidates, and supports a repeatable development pathway focused on fibrotic diseases.
Low Leverage / Debt-freeA debt-free balance sheet materially lowers bankruptcy and interest-rate risk, giving management flexibility in financing R&D or partnering without fixed debt service. Over months, this enhances optionality for licensing deals, equity funding or milestone-led collaborations.
Recent Reduction In Net LossThe marked shrinkage in the 2025 loss versus 2024 implies management has taken durable cost-control actions. If sustained, lower structural burn extends runway, reduces near-term dilution risk and improves the company's ability to reach clinical or partnering milestones.
Bears Say
No Meaningful RevenueThe absence of revenue across multiple years indicates the business has not commercialised products and remains fully pre-revenue. That structural reality forces reliance on external funding, makes cash generation uncertain, and leaves commercial execution unproven over the next several months.
Persistent Negative Cash FlowConsistent annual negative operating and free cash flow shows ongoing cash burn and limited internal funding capacity. Over a 2-6 month horizon this structural cash deficit likely necessitates financing, increasing dilution risk and constraining investment in development or partnerships.
Shrinking Equity And Asset BaseMaterial declines in equity and total assets leave a thin balance sheet buffer against setbacks. A smaller asset base limits collateral and financial flexibility, making it harder to absorb trial delays or secure non-dilutive financing, raising structural funding vulnerability.
Nuformix Plc News
NFX FAQ
What was Nuformix Plc’s price range in the past 12 months?
Nuformix Plc lowest share price was 0.07 p and its highest was 0.56 p in the past 12 months.
What is Nuformix Plc’s market cap?
Nuformix Plc’s market cap is £4.44M.
When is Nuformix Plc’s upcoming earnings report date?
Nuformix Plc’s upcoming earnings report date is Feb 03, 2027 which is in 197 days.
How were Nuformix Plc’s earnings last quarter?
Nuformix Plc released its earnings results on May 28, 2026. The company reported 0 p earnings per share for the quarter, the consensus estimate of N/A by 0 p.
Is Nuformix Plc overvalued?
According to Wall Street analysts Nuformix Plc’s price is currently Overvalued.
Does Nuformix Plc pay dividends?
Nuformix Plc does not currently pay dividends.
What is Nuformix Plc’s EPS estimate?
Nuformix Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nuformix Plc have?
Nuformix Plc has 2,609,750,000 shares outstanding.
What happened to Nuformix Plc’s price movement after its last earnings report?
Nuformix Plc reported an EPS of 0 p in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -2.941%.
Which hedge fund is a major shareholder of Nuformix Plc?
Currently, no hedge funds are holding shares in GB:NFX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nuformix Plc
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
Technical Analysis
Evgen Pharma
―
Futura Medical
―
ImmuPharma
―
OptiBiotix Health
―
HemoGenyx Pharmaceuticals Plc
―